IL262514B2 - Pharmaceutical formulations and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies - Google Patents

Pharmaceutical formulations and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies

Info

Publication number
IL262514B2
IL262514B2 IL262514A IL26251418A IL262514B2 IL 262514 B2 IL262514 B2 IL 262514B2 IL 262514 A IL262514 A IL 262514A IL 26251418 A IL26251418 A IL 26251418A IL 262514 B2 IL262514 B2 IL 262514B2
Authority
IL
Israel
Prior art keywords
antibodies
pharmaceutical compositions
dendritic cell
clinical use
cell antigen
Prior art date
Application number
IL262514A
Other languages
English (en)
Hebrew (he)
Other versions
IL262514B1 (en
IL262514A (en
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of IL262514A publication Critical patent/IL262514A/en
Publication of IL262514B1 publication Critical patent/IL262514B1/en
Publication of IL262514B2 publication Critical patent/IL262514B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL262514A 2016-04-28 2018-10-22 Pharmaceutical formulations and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies IL262514B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662328959P 2016-04-28 2016-04-28
PCT/US2017/029802 WO2017189827A1 (en) 2016-04-28 2017-04-27 Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies

Publications (3)

Publication Number Publication Date
IL262514A IL262514A (en) 2018-12-31
IL262514B1 IL262514B1 (en) 2025-08-01
IL262514B2 true IL262514B2 (en) 2025-12-01

Family

ID=58672794

Family Applications (2)

Application Number Title Priority Date Filing Date
IL262514A IL262514B2 (en) 2016-04-28 2018-10-22 Pharmaceutical formulations and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies
IL321561A IL321561A (en) 2016-04-28 2025-06-17 Pharmaceutical formulations and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL321561A IL321561A (en) 2016-04-28 2025-06-17 Pharmaceutical formulations and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies

Country Status (16)

Country Link
US (2) US20190284281A1 (enExample)
EP (1) EP3448425A1 (enExample)
JP (3) JP7045327B2 (enExample)
KR (5) KR20240033168A (enExample)
CN (2) CN116850282A (enExample)
AU (2) AU2017258191B2 (enExample)
BR (1) BR112018072125A2 (enExample)
CA (1) CA3022116A1 (enExample)
CO (1) CO2018012506A2 (enExample)
EA (1) EA201892443A1 (enExample)
IL (2) IL262514B2 (enExample)
MA (1) MA44763A (enExample)
MX (3) MX2018012945A (enExample)
NZ (2) NZ747504A (enExample)
PH (1) PH12018502278A1 (enExample)
WO (1) WO2017189827A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3672981A4 (en) * 2017-08-22 2021-09-15 Biogen MA Inc. PROCESSES FOR PURIFYING ANTIBODIES PRESENTING REDUCED AGGREGATES WITH HIGH MOLECULAR WEIGHT
WO2020016417A1 (en) 2018-07-19 2020-01-23 Ichnos Sciences S.A. Liquid antibody formulation
KR200494676Y1 (ko) 2020-08-04 2021-12-01 (주) 티나인 버튼식 헤어 염색기
MX2023006474A (es) 2020-12-03 2023-08-16 Biogen Ma Inc Metodos de tratamiento del lupus eritematoso cutaneo y lupus eritematoso sistemico.
WO2023017936A1 (ko) 2021-08-09 2023-02-16 주식회사 인벤테라제약 생체 내 주입 후 대식세포에 의해 탐식 및/또는 대사분해되지 않은 상태로 신장을 통해 소변으로 배출되는 나노 구조물
TW202400652A (zh) * 2022-05-25 2024-01-01 大陸商映恩生物製藥（蘇州）有限公司 抗ｂｄｃａ２抗體及其用途
IL321721A (en) * 2022-12-28 2025-08-01 Duality Biologics Shanghai Co Ltd Antidote conjugation against BDCA2 and its use
WO2025067469A1 (zh) * 2023-09-28 2025-04-03 南京维立志博生物科技股份有限公司 Bdca2单克隆抗体及其和taci组成的融合蛋白及其方法和用途
CN118638234B (zh) * 2024-07-04 2025-10-14 杭州博之锐生物制药有限公司 抗bdca2抗体及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197324A1 (en) * 2003-04-04 2004-10-07 Genentech, Inc. High concentration antibody and protein formulations
WO2014093396A1 (en) * 2012-12-10 2014-06-19 Biogen Idec Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197324A1 (en) * 2003-04-04 2004-10-07 Genentech, Inc. High concentration antibody and protein formulations
WO2014093396A1 (en) * 2012-12-10 2014-06-19 Biogen Idec Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RUDIKOFF, STUART, ET AL., SINGLE AMINO ACID SUBSTITUTION ALTERING ANTIGEN-BINDING SPECIFICITY., 1 March 1982 (1982-03-01) *

Also Published As

Publication number Publication date
KR20240159012A (ko) 2024-11-05
NZ747504A (en) 2025-08-29
NZ787392A (en) 2025-08-29
AU2017258191A1 (en) 2018-11-15
WO2017189827A1 (en) 2017-11-02
BR112018072125A2 (pt) 2019-03-19
KR20220028150A (ko) 2022-03-08
CN116850282A (zh) 2023-10-10
PH12018502278A1 (en) 2019-09-09
MA44763A (fr) 2019-03-06
EA201892443A1 (ru) 2019-04-30
IL262514B1 (en) 2025-08-01
EP3448425A1 (en) 2019-03-06
IL321561A (en) 2025-08-01
AU2024203240A1 (en) 2024-06-13
JP2024038308A (ja) 2024-03-19
MX2025000037A (es) 2025-02-10
KR102366547B1 (ko) 2022-02-23
US20190284281A1 (en) 2019-09-19
JP7045327B2 (ja) 2022-03-31
US20250289895A1 (en) 2025-09-18
KR20240033168A (ko) 2024-03-12
MX2023008075A (es) 2023-07-18
IL262514A (en) 2018-12-31
CA3022116A1 (en) 2017-11-02
MX2018012945A (es) 2019-03-06
AU2017258191B2 (en) 2024-06-13
JP2022084782A (ja) 2022-06-07
CN109475623A (zh) 2019-03-15
KR20250088784A (ko) 2025-06-17
KR20190002563A (ko) 2019-01-08
CN109475623B (zh) 2023-05-26
JP2019520316A (ja) 2019-07-18
CO2018012506A2 (es) 2018-12-14

Similar Documents

Publication Publication Date Title
IL321561A (en) Pharmaceutical formulations and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies
IL310604B1 (en) Pharmaceutical products and stable liquid preparations of IL-17 antibodies
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL270239A (en) Pharmaceutical composition containing bispecific antibody constructs for improved storage and administration
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
UA118441C2 (uk) Антитіло, що розпізнає альфа-синуклеїн
BR112018074155A2 (pt) anticorpo para lag-3, fragmento de ligação ao antígeno e aplicação farmacêutica do mesmo
EP3436482A4 (en) ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
EA201791702A1 (ru) Терапевтические средства на основе гликанов и связанные с ними способы
IL283522A (en) Pharmaceutical preparations containing anti-191p4d12 antibody drug conjugates and methods of using them
IL274160A (en) Methods and compositions for dosing chimeric allogeneic T cells for antigen receptors
SG10202010155YA (en) Compositions and methods for making antibodies based on use of expression-enhancing loci
IL265970B (en) Sulfoxyalkyl organonitro compounds and related compounds and pharmaceutical preparations for use in medicine
IL274578A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
HK1251481A1 (zh) 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法
MX2017003216A (es) Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
IL272495A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
EP2961264A4 (en) METHOD AND COMPOSITIONS FOR PREPARING NUCLEIC ACIDS
EP3434283A4 (en) MEDICAL COMPOSITION WITH A FAB 'FRAGMENT OF A HUMAN ANTI-NGF ANTIBODY AGAINST PEG
IL269094A (en) Antibodies against eutaxin 2 for use in the treatment of liver diseases
HK40005216A (en) Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies
HUP1800273A2 (en) Stable pharmaceutical compositions and process for the preparation thereof
GB201817346D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of diseases
HK40029721A (en) Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies
GB201803563D0 (en) Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases